Jeff is an Endowed Professor at the University of Washington and Director of a Wellstone Muscular Dystrophy Cooperative Research Center
Denis is a Professor of Cancer Biology and Genetics, at the Ohio State University, and Director of the Center of Muscle Health and Neuromuscular Disorders.
AAVogen holds an exclusive license for AVGN7. This proprietary gene therapeutic is based upon the adeno-associated viral platform and can prevent muscle wasting with cancer. AVGN7 also enhances muscle mas and strength in healthy animals and was engineered for superior safety. Global markets are being pursued for a variety of indications in North America, Europe and Asia/Pacific.
AAVogen has capitalized on the expertise of proven leaders in biotech and is positioned for rapid growth. Our CEO, Jade Brown, is the principle of Jade Brown consulting and has over 26 years in the field, 16 in senior-level leadership. The founder and CSO, Dan Rodgers, has over 21 years research and leadership experience. Additional highly experienced partners include:
Dan and Paul are co-discoverers of AVGN7, which was developed through an academic collaboration with many talented and accomplished research partners. Their combined understanding of muscle biology, gene therapy and regenerative medicine is complemented by a Science Advisory Board with field-leading experts in muscle wasting diseases.
We at AAVogen are committed, not only to the science, but mostly to the patients. The fight is personal for us as we recognize that AVGN7 could revolutionize the treatment of muscular dystrophy, for example, or cancer cachexia and aging. If you share our vision, if you share our passion, please help us advance this technology and improve lives.
Dan founded and directed the Washington Center for Muscle Biology and is a former Professor of Molecular Biosciences, both at the Washington State University. He was also an Assistant Professor of Pediatrics at the Johns Hopkins University School of Medicine and received his Ph.D. from the University of California, Berkeley.
Current goals are to complete GLP/toxicology studies in animals, to initiate Phase I clinical trials in lead indication and to expand development into other indications. These include sarcopenia, muscular dystrophies, peripheral neuropathies/nerve damage and heart failure.
Paul directs the Muscle Research & Therapeutics Laboratory at the Baker IDI Heart and Diabetes Research Institute.
Steve is a Distinguished Professor of Biochemistry at the University of Washington and an expert in skeletal and cardiac muscle gene transcription and gene therapy.
Chuck is an Endowed Professor and directs the Institute for Regenerative Medicine as well as the Center for Cardiovascular Biology at the University of Washington.
Our flexible business model is designed around corporate collaborations and to optimize development. A variety of deal structures are being sought and include global or regional rights on all or specific indications, option structures with development milestones and royalty structures that emphasize payments for achieving goals.
AAVogen is advised by highly respected and extremely well established leaders in the research fields of gene therapy, muscle disease and molecular biology. This includes experts in viral gene delivery systems, muscular dystrophies, cancer cachexia, cardiac disease and regenerative medicine. This body of knowledge complements the industry and research expertise of AAVogen's leadership and partners, which together forms a muscle gene therapy dream team.